t’s no surprise that drug-makers Merck and Schering-Plough have decided to merge, said Lionel Laurent in Forbes. The pharmaceutical industry is undergoing a “major facelift” in 2009—the $41-billion Merck-Schering Plough deal comes a little more than a month after Pfizer’s announcement that it was buying rival Wyeth for $68 billion. This is just the kind of consolidation you’d expect as the patents on the companies’ blockbuster drugs expire, threatening profits.
Merck’s Monday announcement of its offer for Schering Plough is still welcome news, said Andrew Willis in the Toronto Globe and Mail. “At a time when many CEOs and boards are fretting about the future, and unwilling to commit cash to takeovers, the big pharmaceutical companies are rationalizing operations and preparing for a better tomorrow.” That should give other businesses a confidence boost.
Maybe, but this is not a sign of strength, said Douglas A. McIntyre in 24/7 Wall Street. No matter how much Merck and Schering-Plough talk about the “synergy” this deal uncorks, it’s all about saving $3.5 billion a year “in a rough economy and in a world where Big Pharma companies are losing many of their profitable drugs as their patents expire.”
THE WEEK'S AUDIOPHILE PODCASTS: LISTEN SMARTER
- Who are the real gay marriage bigots?
- Watch The Daily Show mock Fox News' confused man-crush on Vladimir Putin
- Why is American internet so slow?
- Don't worry: World War III will almost certainly never happen
- What would a U.S.-Russia war look like?
- What the collapse of the Ming Dynasty can tell us about American decline
- Religious liberty should be a liberal value, too
- 10 things you need to know today: March 7, 2014
- The end of academic freedom?
- 4 life hacks from ancient philosophers that will make you happier
Subscribe to the Week